t-cell depleted lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01627275)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- t cell depleted donor lymphocyte
- t-cell depleted lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997471 | Phase 1 | Jun 30, 2025 | Autonomous University of Madrid |
| NCT05350163 | Phase 1 | Apr 5, 2022 | Baptist Health, Miami Cancer Institute |
| NCT00986518 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | University of Paris |
| NCT01627275 | Phase 1 | Jun 1, 2012 | Duke University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Autonomous University of Madrid | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Baptist Health | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Miami Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2012 |
5 organizations
Page 1 / 1